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ARTICLE
Paradoxical activation of the protein kinase-
transcription factor ERK5 by ERK5 kinase inhibitors
Pamela A. Lochhead 1✉, Julie A. Tucker 2, Natalie J. Tatum 3, Jinhua Wang 4,5, David Oxley1,
Andrew M. Kidger 1, Victoria P. Johnson 1,6, Megan A. Cassidy1, Nathanael S. Gray4,5,
Martin E.M. Noble 3 & Simon J. Cook 1✉
The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and
inﬂammation, and small-molecule ERK5 kinase inhibitors have been developed. However,
selective ERK5 kinase inhibitors fail to recapitulate ERK5 genetic ablation phenotypes, sug-
gesting kinase-independent functions for ERK5. Here we show that ERK5 kinase inhibitors
cause paradoxical activation of ERK5 transcriptional activity mediated through its unique
C-terminal transcriptional activation domain (TAD). Using the ERK5 kinase inhibitor, Com-
pound 26 (ERK5-IN-1), as a paradigm, we have developed kinase-active, drug-resistant
mutants of ERK5. With these mutants, we show that induction of ERK5 transcriptional activity
requires direct binding of the inhibitor to the kinase domain. This in turn promotes con-
formational changes in the kinase domain that result in nuclear translocation of ERK5 and
stimulation of gene transcription. This shows that both the ERK5 kinase and TAD must be
considered when assessing the role of ERK5 and the effectiveness of anti-ERK5 therapeutics.
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xtracellular signal-regulated kinase 5 (ERK5, also known as
Big MAP Kinase or BMK1)1,2 is a member of the mitogen-
activated protein kinase (MAPK) family, which also
includes ERK1/23, the JNKs4 and the p38 kinases5. Like ERK1/2,
ERK5 is the effector kinase of a three-tiered MAPK pathway,
comprising MEKK2 and MEKK3 (the MKKKs), MEK5 (MKK)
and ﬁnally ERK5 (MAPK). ERK5 is encoded by the MAPK7 gene
and includes an N-terminal kinase domain that shares 50%
identity with ERK21,2. However, it also contains a large, unique
C-terminal extension that includes a nuclear localisation signal
(NLS) and a transcriptional activation domain (TAD) (Fig. 1a)6.
The ERK5 pathway is activated by mitogens7, agonists of the Toll-
like receptor-28 and cellular stresses9. Upon cellular stimulation,
activated MEK5 phosphorylates the TEY motif in the ERK5
activation-loop, leading to activation of its kinase domain10. The
ERK5 C-terminus also becomes auto-phosphorylated and pro-
motes ERK5 translocation from the cytosol to the nucleus11,12,
where ERK5 has been shown to interact with MEF2 transcription
factors such as MEF2D7,13,14. The C-terminus can also be regu-
lated by other protein kinases, including ERK1/215 and
CDK116,17, which phosphorylate C-terminal residues indepen-
dently of ERK5 kinase activity. Thus, the C-terminus mediates
some of the effects of ERK5 kinase activity and integrates signals
from other pathways.
There is a growing appreciation of the role that
ERK5 signalling plays in some diseases, most notably in inﬂam-
mation and cancer. For example, ERK5 plays a pro-inﬂammatory
role in human endothelial cells and monocytes8,18 and ERK5
inhibition exerts an anti-inﬂammatory effect. ERK5 is also
implicated as a mediator of inﬂammation-driven cancer19,20.
Finally, a range of studies have suggested that ERK5 signalling
promotes cell proliferation, cell survival and motility and inva-
sion21–23. While MEK5 or ERK5 mutations are rare in cancer,
these components are sometimes over-expressed; indeed, MAPK7
is ampliﬁed in hepatocellular carcinoma (HCC)24, although it
appears not to drive HCC cell proliferation25. In addition, ERK5
is activated in melanoma cells with BRAF mutations26 and such
cells can acquire resistance to the BRAF inhibitor vemurafenib by
increasing ERK5 phosphorylation27. Thus, ERK5 may drive key
cancer hallmarks and promote resistance to other targeted agents.
These observations have prompted commercial and academic
MEK5 or ERK5 drug discovery programmes in the hope of
developing novel anti-inﬂammatory or anti-cancer therapeutics.
Commercial MEK5 or ERK5 inhibitor programmes include
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Fig. 1 Schematic diagrams of the reagents used in this study. a Schematic diagram of ERK5 (full length) and ERK5 ΔTAD, which lacks the C-terminal
extension. Functional domains with amino acid positions are: cytosolic targeting domain (1–77), kinase domain (48–383), activation-loop TEY motif
(219–221), proline rich domain (PR) 1 (434–485) and 2 (578–701), nuclear localisation signal (NLS) (505–539), minimal transactivation domain (TAD)
(664–789), and the N-terminal interaction domain (740-816). b Chemical structures of ERK5i: compounds 25, 26 and AX15836. c Schematic
representation of the ERK5:MEF2D luciferase assay. d Chemical structure of the MEK5i, BIX02189. Structures were drawn using ChemDraw v16.0.
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ActivX, Kyorin Pharmaceutical Co.28, Bayer AG29, Boehringer
Ingelheim30 and AstraZeneca31. The ﬁrst ERK5 inhibitor (ERK5i)
to be described was XMD8-92 from the Dana-Farber Cancer
Institute and the Scripps Research Institute, USA32,33. Using the
KiNativ method34,35 XMD8-92 was found to inhibit ERK5 with
an IC50 of 1.5 µM, being tenfold more selective than its most
potent off-target kinases. In cells both siRNA knockdown of
ERK5 or XMD8-92 treatment caused an increase in p21CIP1 gene-
expression, and XMD8-92 or expression of a dominant-negative
ERK5 (AEF: where the activation-loop TEY phosphorylation sites
are mutated to AEF) decreased tumour growth32,33. The sub-
sequent ERK5 inhibitors, compounds 25 and 26 (Fig. 1b), were
generated through a collaboration between the Dana-Farber
Cancer Institute, USA, and the Structural Genomics Consortium
in Oxford, UK and others. Compounds 25 and 26 (also known as
ERK5-IN-1 and XMD17-109) are more potent than XMD8-92,
and compound 26 represents a further improvement in selectivity
over XMD8-9236,37. Recently, AX15836 (Fig. 1b), a new, more
potent and more selective ERK5 inhibitor was developed at
ActivX Biosciences Inc, USA and Kyorin Pharmaceutical Co.,
Japan28. Notably, AX15836 did not share with XMD8-92 the
ability to block immune responses or inhibit tumour cell pro-
liferation. This led to the discovery that XMD8-92 derived most
of its biological activity from off-target interactions with
bromodomain-containing proteins such as BRD4. Thus, dual
ERK5-BRD inhibitors, such as XMD8-92 and compound 26, are
no longer suitable for dissecting the contribution that ERK5 plays
within the cell. Selective ERK5 inhibition, without activity against
BRD proteins, can be achieved with AX15836 or the new ERK5i
compound 4638 making them useful small molecules for inter-
rogating the cellular roles of ERK5. Critically, AX15836 failed to
replicate the effects of genetic ablation of ERK5 on cytokine
release from immune cells or cell proliferation28. The authors
suggested that this disconnect between ERK5 kinase inhibition
and ablation of ERK5 expression was evidence of kinase-
independent effects of ERK5 signalling28.
Here, we provide an important new insight into this by
showing that a variety of ERK5 inhibitors, including compounds
25 and 26 but also AX15836, while being very effective at inhi-
biting the ERK5 kinase domain cause a paradoxical activation of
the ERK5 transcriptional activation domain and drive ERK5-
dependent gene transcription. Critically our study suggests that
both the ERK5 kinase domain and the ERK5 TAD must be
considered when validating the role of ERK5 in biological pro-
cesses, in diseases where ERK5 is implicated and in designing and
assessing the effectiveness of anti-ERK5 therapeutics.
Results
ERK5i induce transcriptional activity in the ERK5:MEF2D
reporter system independently of kinase activity. The paucity of
well-validated ERK5 substrates led us to use an ERK5-dependent
transient transfection reporter assay to determine the ‘in cell’ IC50
of small-molecule ERK5 kinase inhibitors (ERK5i). This system
(Fig. 1c) comprised: (i) a constitutively active form of the ERK5
kinase MEK5, MEK5D (where the regulatory activation-loop
phosphorylation sites in MEK5 are mutated to phospho-mimetic
aspartic acid, producing a constitutively active form of MEK5), to
phosphorylate and activate ERK5; (ii) HA-tagged, full length
human ERK5; (iii) a fusion protein of the transactivation domain
(TAD) of MEF2D and the DNA binding domain of the yeast
transcription factor GAL4 (MEF2D is one of the few validated
ERK5 substrates and interacting proteins6,7,14,39); (iv) a luciferase
reporter construct with upstream multimerised GAL4 binding
sites and (v) a Renilla reporter construct that is regulated by the
constitutive CMV promoter as a transfection control. In this
system, MEK5D phosphorylates the activation-loop of ERK5
causing activation of its kinase domain. The kinase domain of
ERK5 then phosphorylates the MEF2D TAD leading to activa-
tion, thereby driving luciferase expression, which serves as a
readout of ERK5 kinase activity. We previously validated this
system and used it to monitor ERK5 activity25,40,41. The ERK5
inhibitors compound 26, compound 2532,37, AX1583628 (Fig. 1b)
and MEK5 inhibitor BIX0218930 (Fig. 1d) were used in our
studies.
To measure the IC50 of ERK5i, transfected cells (as described
above (Fig. 1c)) were incubated with increasing concentrations of
inhibitors and luciferase activity measured. Compound 26 caused
a dose-dependent decrease in MEK5D-driven luciferase activity;
however the dose–response curve never reached zero, with
30–40% of maximal luciferase activity persisting, even at higher
concentrations (Fig. 2a). This effect was also seen with compound
25 (an ERK5i similar to compound 26) (Fig. 2b). Compound 26
also inhibits the bromodomain and extra terminal (BET) domain
family member, BRD4, a protein that binds acetylated lysines and
plays a role in gene regulation. To control for BRD4 being
responsible for the residual activity in the ERK5:MEF2D assay we
used AX15836 an ERK5i that has no BRD4 activity28. Strikingly
AX15836 caused a paradoxical increase in ERK5:MEF2D-
dependent luciferase expression over and above that seen with
MEK5D (Fig. 2c).
We speculated that the residual activity that remained for
compounds 25 and 26, and the increase in activity with AX15836
was due to an ERK5-mediated induction of MEF2D activity in
response to ERK5i binding. To test if ERK5i were able to drive
ERK5:MEF2D activity in this assay we repeated these experiments
but omitted MEK5D, so that ERK5 was un-phosphorylated and
inactive (‘non-activated full length ERK5’). Indeed, compounds 26,
25 and AX15836 all elicited a dose-dependent increase in ERK5:
MEF2D luciferase activity. Moreover, for compounds 26 and 25 the
level of induced activity was the same as the residual activity seen
when MEK5D was present (Fig. 2a–c comparing ‘non-activated full
length ERK5’ with ‘MEK5D-activated full length ERK5’).
The C-terminus of ERK5 contains a transcriptional transacti-
vation domain (TAD)6 (Fig. 1a), which is known to interact with
MEF2D6. To test if the C-terminus was responsible for the
residual activity we produced a mutant of ERK5 (termed
ERK5ΔTAD) that lacked the C-terminal extension, mimicking a
naturally occurring ERK5 splice variant42 (Fig. 1a). MEK5D
activated both full length ERK5 and ERK5ΔTAD equally in this
system (Fig. 2d). Using MEK5D to activate ERK5ΔTAD we saw
complete, saturable inhibition of ERK5:MEF2D-dependent luci-
ferase activity with compounds 25, 26 and AX15836 (Fig. 2a–c)
consistent with their ERK5 kinase inhibitory activity. In
agreement with the paradoxical activation of ERK5 being
mediated by its C-terminal extension, there was no induction of
luciferase activity when non-activated ERK5 ΔTAD (not activated
by MEK5D) was incubated with either compounds 25, 26 or
AX15836 (Fig. 2a–c). Furthermore, using successive C-terminal
deletion mutants we mapped the region responsible for
compound 26-induced transcriptional activation of ERK5:
MEF2D to the previously reported minimal TAD (for more
information see Supplementary Fig. 1).
The activation of ERK5:MEF2D seen with ERK5i was not seen
when we used the MEK5 inhibitor, BIX02189; when tested with
full length ERK5, BIX02189 fully inhibited ERK5:MEF2D
luciferase activity with an IC50 of ~500 nM (Fig. 2e). To test if
ERK5 kinase activity was required for paradoxical activation of
ERK5 we repeated the same experiments with a kinase-dead
mutant of ERK5 in which the catalytic aspartic acid was mutated
to alanine (D182A), (Fig. 2f); both compounds 26 and
AX15836 stimulated ERK5-dependent expression of luciferase
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by MEF2D with either wild type or kinase dead ERK5 (Fig. 2g, h).
Phosphorylation of the ERK5 C-terminus and MEF2D promotes
transcriptional activity. We therefore assessed C-terminal phos-
phorylation and MEF2D phosphorylation in the presence of
MEK5D, compound 26 and AX15836. Although compounds
26 and AX15836 promoted phosphorylation of S754 in the ERK5
C-terminus, this was not required for ERK5i induced ERK5:
MEF2D activity (Supplementary Fig. 2). Furthermore, we
identiﬁed 18 MEK5-ERK5-driven phosphorylation sites on
MEF2D, but phosphorylation of MEF2D was not induced by
compound 26 or AX15836 (for more information see Supple-
mentary Fig. 3 and Supplementary Table 1).
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Fig. 2 ERK5i induce transcriptional activity in the ERK5:MEF2D reporter system independently of kinase activity. a, b, c and e HEK293 cells were
transfected with GAL4-MEF2D, GAL4:LUC and CMV:Renilla, together with either wild-type HA-ERK5 (full length) or HA-ERK5 ΔTAD and EGFP-MEK5D or
EGFP (control) as indicated. Four hours post transfection, cells were treated with either DMSO (control) or compound 26 (a), compound 25 (b), AX15836
(c) or BIX02189 (e) at concentrations indicated. Twenty-four post transfection, cells were lysed and ﬁreﬂy luciferase activity was measured and normalised
to Renilla. The results are presented as the mean of three independent experiments ± SEM. Source data are provided as a Source Data ﬁle. d HEK293 cells
were transfected as in (a). Twenty-four hours post transfection cells were lysed and processed as in a. f HEK293 cells were transfected with GAL4-MEF2D,
GAL4:LUC and CMV:Renilla together with either wild-type HA-ERK5 (full length) or HA-ERK5 kinase dead and EGFP-MEK5D or EGFP (control) as
indicated. Twenty-four hours post transfection cells were lysed and processed as in a. g and h HEK293 cells were transfected as in (f). Four hours post
transfection, cells were treated with either DMSO (control) or compound 26 (g) or AX15836 (h) at concentrations indicated. Twenty-four hours post
transfection cells were lysed and processed as in (a).
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Taken together these results demonstrated that while com-
pounds 25, 26 or AX15836 are all very effective inhibitors of
ERK5 kinase activity, they also promote paradoxical activation of
the ERK5 C-terminal TAD. This effect does not require ERK5
kinase activity, ERK5 or MEF2D phosphorylation and is not
shared with MEK5i (BIX02189), suggesting it is unique to those
compounds that bind to ERK5.
Generation of compound 26-resistant, kinase-active mutants of
ERK5. In cell-based assays, compounds may exhibit off-target
effects, which create false positives. These include: (i) activation of
stress responses that may signal to ERK5; (ii) indirect effects on
luciferase expression by affecting the transcriptional and trans-
lational machinery, or (iii) direct effects on luciferase activity.
Therefore, it was critical to determine whether the transcriptional
activation by ERK5i in the ERK5:MEF2D assay was a result of
direct binding of ERK5i to the ERK5 kinase domain and not an
off-target effect. We, therefore, set out to generate ERK5 mutants
that lacked the ability to bind compound 26 but retained kinase
activity.
The X-ray crystal structure of the kinase domain of ERK5 in
complex with compound 2537 and pan-kinase binding selectivity
data for the highly similar compound 2636 suggested that the
presence of a small residue immediately prior to the DFG motif,
at the start of the activation-loop (G199 in ERK5), combined with
a leucine in the base of the ATP-binding pocket (L189 in ERK5),
was important to accommodate the cyclopentyl substituent of
compounds 25 and 26 (Fig. 3a, b). This combination of residues,
although common among kinases more generally, is rare in
members of the MAPK family, being found only in ERK5
(Fig. 3c). ERK1, ERK2, ERK7 and NLK, all have a cysteine at the
position equivalent to ERK5 G199 combined with a leucine at the
position equivalent to ERK5 L189, and these kinases are not
inhibited by compound 26. By contrast, ERK3 and ERK4, and the
polo-like kinases PLK1, PLK2 and PLK3, which are also not
inhibited by compound 26, all have glycine at the position
equivalent to G199 in ERK5, while the residue equivalent to
ERK5 L189 is the bulkier phenylalanine. We hypothesised
therefore that introducing individual mutations in the ATP-
binding site of ERK5 of L189 to phenylalanine (L189F) and G199
to cysteine (G199C) would generate mutant ERK5 variants
resistant to inhibition by compound 26, while retaining kinase
activity. Elkins et al.37 postulate that binding afﬁnity and
selectivity are also driven by hydrophobic interaction of I115 at
the back of the ATP-binding pocket with the N-methyl
substituent of compounds 25 and 26. Comparison of binding
data and sequence conservation across the family of DCLKs
suggested that replacement of I115 with valine (as observed in
DCLK1 and 3) would negatively impact binding of compounds
25 and 26 (Fig. 3a–c), again generating a kinase-active but
inhibitor-resistant mutant. Finally, the presence of aspartate
(D143 in ERK5) at the mouth of the ATP-binding pocket just C-
terminal to the hinge region is proposed to contribute to tight
binding of compounds 25 and 26 by securing the hinge-binding
moiety in place37 (Fig. 3a, b). The side-chain of D143 forms a
helix cap, stabilising the short αD helix, which follows the hinge
region (Supplementary Fig. 4A). Structure-guided sequence
alignments across the kinome show that this residue is often an
amino acid such as aspartate, asparagine, glutamate or serine,
which can form a helix cap (Supplementary Fig. 4B)43; truncation
to glycine (D143G) removes both the steric constraints imposed
on compound binding and the αD helix cap.
We undertook molecular dynamics simulations of compound
26 bound to wild-type ERK5, as well as mutants I115V, D143G,
L189F and G199C to predict relative binding energies by the
MM/PBSA method (Fig. 3d). We noted no signiﬁcant changes in
the ﬂexibility of either the ligand or the binding site (Supple-
mentary Fig. S4C, D) over the short simulation time; however, as
anticipated, we observed unfavourable changes to the binding
energies of all mutants, with statistically signiﬁcant reductions for
mutants I115V and L189F compared to wild-type. Converting the
differences in binding energy to estimate a log-fold change in
binding afﬁnity (Fig. 3e), predicted notably weaker binding of
compound 26 to all the ERK5 mutants simulated, with the
binding position of compound 26 compromised by all mutations
(Fig. 3f–i).
We generated these mutants and expressed them in the
presence and absence of MEK5D. MEK5D was able to
phosphorylate all of the mutants on the TEY motif, albeit
D143G to a lesser extent than the others (Fig. 3j). An ERK5
band-shift was observed for wild type, I115V, L189F and
G199C but not kinase dead or D143G, suggesting that D143G
lacks kinase activity. Consistent with this, phosphorylation of
T733, a known autophosphorylation site was detected on wild
type, I115V, L189F and G199C but not kinase dead or D143G.
Furthermore, S754 phosphorylation (another ERK5 autopho-
sphorylation site) was increased following MEK5D expression
on wild type, I115V, L189F and G199C, but not kinase dead or
D143G. Interestingly, G199C had higher basal S754 phosphor-
ylation than wild type (Fig. 3j). As we saw a MEF2D band-shift
when ERK5 was activated with MEK5D in Supplementary
Fig. 3C, we used this as a readout of ERK5 kinase activity in
cells; this demonstrated that wild type, I115V, L189F and
G199C were all active MEF2D kinases, whereas D143G was not
(Fig. 3j). Next, we assessed the activity of these mutant forms of
ERK5 in the ERK5:MEF2D luciferase assay; L189F and G199C
had a higher basal activity compared to wild type and I115V,
L189F and G199C were all activated by MEK5D, whereas
D143G was not (Fig. 3k). Thus, we were able to generate three
kinase-active ERK5 mutants with predicted reduced binding
ability for compound 26.
Binding of compounds 26 or AX15836 to the ERK5 kinase
domain is required for paradoxical ERK5:MEF2D transcrip-
tional activation. We conducted dose–response experiments
comparing the predicted compound 26-resistant ERK5 mutants
with wild-type ERK5 in the ERK5:MEF2D assay. With non-
activated ERK5, L189F and G199C were both completely resistant
to compound 26 with no induction of ERK5:MEF2D (Fig. 4a, b),
while I115V and D143G had reduced sensitivity to compound 26
compared to wild type so that the induction curve shifted to the
right (Fig. 4c, d). For MEK5D-activated ERK5 we assessed the
effects on L189F, G199C and I115V, but not D143G (as it could
not be activated). L189F, G199C and I115V ERK5 mutants each
showed a reduction in sensitivity to compound 26, with the effect
more notable for L189F and G199C compared to I115V
(Fig. 4e–g). This is consistent with the induction of non-activated
ERK5:MEF2D transcriptional activity for these mutants.
AX15836 is a derivative of XMD8-92 and compound 26, so we
speculated that the compound 26 drug-binding mutants would
also be resistant to AX15836. We therefore repeated the
dose–response experiments comparing the compound 26-resis-
tant ERK5 mutants to wild type in the ERK5:MEF2D assay. With
non-activated ERK5, L189F and G199C were both completely
resistant to AX15836 (Fig. 4h–i) and I115V and D143G had a
reduced effect (Fig. 4j–k), comparable to compound 26.
These results conﬁrmed the structural predictions that I115V,
D143G, L189F and G199C would reduce binding of compound
26 to ERK5. These mutants fell into two groups; those on which
compound 26 had little or no effect (L189F and G199C), and
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those on which compound 26 had a reduced effect (I115V and
D143G). These mutants exhibited similar responses to AX15836.
Signiﬁcantly, these results showed that direct binding of
compound 26 or AX15836 to the ERK5 kinase domain was
required for the paradoxical drug-induced activation of ERK5:
MEF2D transcriptional activity, conﬁrming that compound 26 or
AX15836 were acting ‘on target’ to activate the ERK5 TAD.
Compound 26 and AX15836 promote ERK5 nuclear localisa-
tion. In its inactive state, ERK5 is predominantly cytosolic and
translocates into the nucleus upon activation by MEK512. This is
regulated by an intramolecular interaction between the N-
terminal kinase domain and the C-terminus, which ensures
mutual repression of the kinase and TAD functions; this is de-
repressed by MEK5-catalysed phosphorylation of ERK5, which
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activates the kinase domain and exposes the NLS and TAD11,12.
In order to determine if compound 26 or AX15836 mimic
MEK5D by disrupting this interaction, we co-expressed the HA-
ERK5 ΔTAD mutant (i.e., just the kinase domain) with GST-
ERK5C-term. Pulldown with glutathione Sepharose beads
showed that the HA-ERK5ΔTAD associated with the GST-
ERK5C-term; furthermore, expression of MEK5D to drive TEY
phosphorylation of HA-ERK5ΔTAD caused it to dissociate from
GST-ERK5C-term (Fig. 5b). Compound 26 and AX15836 both
caused a dose-dependent dissociation of HA-ERK5ΔTAD from
the GST-ERK5C-term despite failing to promote TEY phos-
phorylation. As a control we used an ERK1/2 inhibitor,
SCH77298444, which is inactive towards ERK5. SCH772984 had
no effect demonstrating that it was an ERK5i selective effect
(Fig. 5a). To show that SCH772984 was active in cells, we
expressed myc-BRAFV600E to stimulate ERK1/2 activity and
measured phosphorylation of T359 on RSK, an ERK1/2 phos-
phorylation site. SCH772984 was active as it blocked this phos-
phorylation (Fig. 5b).
Prompted by this we assessed whether compound 26 or
AX15836 treatment led to the exposure of the NLS to promote
ERK5 nuclear translocation. We expressed HA-ERK5 in HeLa cells
and imaged HA-ERK5 localisation using ﬂuorescence microscopy.
In untreated cells the majority of HA-ERK5 was seen in the
cytosol. As a positive control, we co-expressed EGFP-MEK5D,
which increased HA-ERK5 nuclear staining. Next, we assessed the
effects of compound 26 or AX15836 and also observed an increase
in HA-ERK5 nuclear staining (Fig. 5c). We used high-content
ﬂuorescence microscopy to score the number of cells with a higher
nuclear to cytosolic staining for HA-ERK5. Using this method, we
again observed that co-expression of MEK5D increased HA-ERK5
nuclear translocation, as expected. We also demonstrated that
compound 26 or AX15836 promoted HA-ERK5 nuclear transloca-
tion in a dose-dependent manner (Fig. 5d, e). An increase in HA-
ERK5 nuclear localisation in response to compound 26 or
AX15836 was seen after 15min, plateaued at 1 h (Fig. 5f) and
was sustained for up to 24 h (Fig. 5d, e). Consistent with these
experiments we also saw an increase in endogenous ERK5 in the
nucleus following treatment of HeLa cells with compound 26 or
AX15836 (Fig. 5g).
We extended these experiments to determine the cellular
localisation of the compound 26-resistant ERK5 mutants and the
effects of compound 26 on these mutants. For the drug-resistant
mutants, I115V staining was mostly cytosolic, similar to wild-type
ERK5. D143G and L189F exhibited a higher basal nuclear
staining than wild type. G199C had an increased nuclear staining
with 80% of cells having more G199C staining in the nucleus than
in the cytosol (Fig. 5h). These results reﬂected the basal ERK5:
MEF2D activity measured in Fig. 3k (with the exception of
D143G, which had a basal ERK5:MEF2D activity that was
comparable to wild-type ERK5). The compound 26-resistant
mutants had an attenuated nuclear localisation in response to
compound 26 treatment. For I115V the effect of compound 26
was slightly reduced at 0.1 µM but exhibited a similar effect to
wild type at 1 µM (Fig. 5i), as was seen with ERK5:MEF2D
activity in Fig. 4c. D143G, L189F and G199C localisation was
resistant to compound 26 treatment (Fig. 5i), consistent with the
attenuated effect of compound 26 on the ERK5:MEF2D activity
of these mutants shown in Fig. 4.
These results not only showed that compound 26 or AX15836
cause exposure of the NLS and TAD, driving nuclear localisation
of ERK5, but also that the level of nuclear localisation of ERK5
correlated with transcriptional activity (comparing the nuclear
localisation of the ERK5 compound 26-resistant mutants with
basal ERK5:MEF2D activity), and provided further evidence that
the compound 26-resistant mutants were less responsive to
compound 26.
Compound 26 and AX15836 activate expression from the
KLF2 promoter. Finally, we wanted to assess the effects of ERK5i
on an ERK5-regulated promoter. To this end, we used KLF2 that
is known to be regulated by ERK5 and MEF2D44. We expressed a
luciferase reporter regulated by −924/+14 bp of the 5′UTR of the
KLF2 gene. Co-expression of EGFP-MEK5D was able to increase
KLF2 reporter activity 3.5-fold; acting through endogenous ERK5
and MEF2D. Expression of MEF2D and ERK5 increased KLF2
reporter activity 15-fold in the presence of MEK5D conﬁrming
their role in regulating the KLF2 promoter (Fig. 6a). We used this
system to measure the effects of compound 26 or AX15836 on
endogenous ERK5. Both of these ERK5i increased KLF2
Fig. 3 Generation of compound 26-resistant kinase-active mutants of ERK5. a, b Compound 25 (carbon atoms in green) bound to the ATP-binding
pocket of ERK5 (PDB 4B9937). Side-chains of residues proposed by Elkins et al.37 as key to the selectivity and binding afﬁnity of 25 for ERK5 are shown in
ball-and-stick and coloured blue (Ile115), purple (Leu189), gold (Gly199) and coral (Asp143), respectively. Asp200 from the ‘DFG’ motif at the start of the
activation-loop (red), and Met140 in the hinge region (grey) are also shown. A transparent molecular surface is drawn over compound 25. Hydrogen bonds
between 25 and ERK5 are shown as black dashed lines. The view in (b) is rotated ~90° about a vertical axis compared to the view in (a). Figure prepared
using CCP4MG84. c Comparison of sequences across the DCLK, ERK and PLK families highlights conservation of Ile115, Leu189 and Gly199 (ERK5
numbering), respectively, as key to inhibition by compounds 25 and 26. Sequences were retrieved from the UniProt database85, aligned using Clustal
Omega86, and the alignment coloured by sequence identity (where darker blue indicates higher conservation) and annotated using Jalview87. d Calculated
binding energies for compound 26 to wild-type ERK5, and the mutant variants I115V, D143G, L189F and G199C, as derived from molecular dynamics
simulations and MM/PBSA calculation (unadjusted for entropic contribution); the reduction in binding energy is statistically signiﬁcant by one-way
ANOVA for binding of compound 26 to mutants I115V (p= 0.0282) and L189F (p= 0.0149) when compared to binding to wild-type ERK5. Source data are
provided as a Source Data ﬁle. e Estimated log-fold change in Kd derived from calculated binding energies demonstrating notably weaker afﬁnity of
compound 26 for all mutant variants of ERK5 compared to wild-type. Source data are provided as a Source Data ﬁle. f–i Comparison of compound 26
binding to ERK5 wild-type (grey) and I115V (f, blue), D143G (g, coral), L189F (h, purple) or G199C (i, gold) in silico, derived from molecular dynamics
simulations with wild-type and mutated residue shown as sticks to denote mutation site. The D143G mutation causes compound 26 to shift toward the P-
loop. The I115V, L189F and G199C mutations cause compound 26 to shift out into a shallower binding position in the active site, resulting in the weaker
binding energies observed. Figures were prepared using UCSF Chimera. j HEK293 cells were transfected with FLAG-MEF2D and either wild-type HA-ERK5,
kinase dead HA-ERK5, HA-I115V ERK5, HA-D143G ERK5, HA-L189F ERK5 or HA-G199C ERK5, and either EGFP-MEK5D or EGFP. Twenty-four hours post
transfection cells were lysed, subjected to SDS-PAGE and immuno-blotted with the antibodies shown. The experiment was repeated three times and a
representative image is shown. k HEK293 cells were transfected with GAL4-MEF2D, GAL4:LUC and CMV:Renilla, together with either wild-type HA-ERK5,
HA-ERK5 ΔTAD, HA-I115V ERK5, HA-D143G ERK5, HA-L189F ERK5 or HA-G199C ERK5 and either EGFP-MEK5D or EGFP. Twenty-four hours post
transfection, cells were lysed and ﬁreﬂy luciferase activity was measured and normalised to Renilla. The results are presented as the mean of at least three
independent experiments ± SEM. Source data are provided as a Source Data ﬁle.
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promoter activity in a dose-dependent manner; however, the
dose-dependency for each compound was different. The effect of
compound 26 peaked at 300 nM before reducing at higher con-
centrations, whereas the induction observed with AX15836
increased as the concentration of drug increased (Fig. 6b). To test
if the bi-phasic effect of compound 26 was due to the induction of
S754 phosphorylation (Supplementary Fig. 2), we repeated this
experiment comparing the effects of over-expressed wt ERK5
with the ERK5 S754A mutant, but both wt and the S754A mutant
were inhibited at higher concentrations of compound 26
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(Supplementary Fig. 5). However, as compound 26 is known to
inhibit BRD4, we tested to see if KLF2-luciferase reporter activity
was sensitive to BRD4 inhibition using JQ1. At 0.1 µM JQ1
KLF2 reporter activity was inhibited by ~30% (Supplementary
Fig. 6). This suggests that at higher concentrations of compound
26 (>1 µM) the reduction in KLF2-luciferase reporter activity may
be due to BRD4 inhibition. Notably, AX15836, which does not
inhibit BRD428, did not cause inhibition at high doses (Fig. 6b).
We then tested the role of the C-terminus of ERK5 using the
KLF2 reporter system, with MEK5D as a positive control. Here,
300 nM AX15836 increased full length ERK5 driven KLF2
reporter activity and this was dependent on the C-terminus of
ERK5 as the ERK5ΔTAD was unable to support KLF2 promoter
activity in the presence of AX15836 or MEK5D (Fig. 6c). These
results demonstrate that ERK5i are able to drive paradoxical
transcriptional activation of a canonical ERK5-regulated gene, as
well as the ERK5:MEF2D system.
Discussion
The identiﬁcation of ERK5 as a potential anti-cancer and anti-
inﬂammatory drug target has seen academic groups and phar-
maceutical companies invest in developing small-molecule inhi-
bitors of the ERK5 kinase domain (ERK5i). Kinases are attractive,
‘druggable’ targets due to their active site lying in a deep cleft
between the canonical N- and C-terminal lobes and by 2015, 28
kinase inhibitors had received US FDA approval45. However,
intensive research and clinical experience have identiﬁed two
main problems that affect the efﬁcacy of kinase inhibitors: (i)
innate or acquired resistance to the kinase inhibitor due to
mutation of the intended target46, mutation of other pathway
components or pathway remodelling47 and (ii) unintended acti-
vation of the target pathway48, either by inhibition of negative
feedback pathways49 or through inhibitor binding to the kinase
resulting in paradoxical activation (the latter termed ‘inhibitor
hijacking of kinase activation’ by Okuzumi et al.50).
Our results show that ERK5i bind directly to the ERK5 kinase-
active site and subsequently promote a conformational change in
the kinase domain that dissociates the NLS and transcriptional
activation domain (TAD), driving nuclear translocation of ERK5
and stimulation of a known ERK5-regulated promoter (KLF2).
Therefore, ERK5i binding causes paradoxical activation of the
ERK5 TAD and its downstream targets. Use of ERK5i that acti-
vate the ERK5 TAD and ERK5-dependent pathways may not
only hinder research into deﬁning the role of ERK5 in cells but
may also impede the therapeutic potential of ERK5i. To aid the
development of ERK5 inhibitors as potential therapeutics and
tool compounds we set out to understand how ERK5i
activated ERK5.
Several lines of evidence indicate that ERK5i elicit paradoxical
TAD activation by binding directly to the kinase-active site rather
than through off-target effects or feedback loops. Multiple feed-
back loops function in the ERK1/2 pathway (reviewed in Caunt
et al.)51 and although none have been described to date for the
ERK5 pathway they are likely to exist. We therefore set out to
address if inhibition of ERK5 by ERK5i repressed a negative
feedback loop, leading to activation of a non-inhibitor bound
pool of ERK5 that could lead to pathway output. First, we used
kinase dead ERK5. Had ERK5 kinase activity been required for
paradoxical pathway activation then kinase dead ERK5 would be
insensitive to ERK5i. However, both compound 26 or AX15836
‘activated’ kinase dead ERK5 in the ERK5:MEF2D assay (Fig. 2).
In addition, we did not see an increase in phosphorylation of the
TEY motif in the ERK5 activation-loop with compound 26 or
phosphorylation of the ERK5 substrate MEF2D showing that
neither MEK5 nor ERK5 kinase activity was activated in the
presence of ERK5i (Supplementary Figs. 2 and 3). Further evi-
dence against a negative feedback loop came from the MEK5
inhibitor, BIX02189. If inhibition of ERK5 blocked a feedback
loop to reactivate the pathway then MEK5 inhibition would be
expected to do the same; indeed, this is seen with MEK1/2
inhibitors in cells with wild-type BRAF51. In fact, BIX02189 fully
inhibited ERK5:MEF2D activity; no residual activity or pathway
activation was seen (Fig. 2). Taken together, these results argue
against a feedback mechanism being responsible for increased
output of ERK5 activity in the presence of ERK5i. To rule out any
off-target mechanisms we generated ERK5i-insensitive, kinase-
active mutants of ERK5 (Fig. 3). These fell into two classes with
attenuated sensitivity to compound 26; mutations that reduced
the effect of compound 26 (I115V and D143G) and those that
blocked the effect of compound 26 (L189F and G199C) on ERK5:
MEF2D transcriptional activity (Fig. 4). These mutations also
blocked ERK5 nuclear localisation in response to compound 26
(Fig. 5). Taken together, these results show that it is the direct
binding of the inhibitors (compound 26 or AX15836) to the
ERK5 kinase-active site that promoted paradoxical activation.
How does binding of ERK5i to the kinase domain activate
ERK5 transcriptional activity? The ERK5 kinase domain and
TAD are known to reciprocally repress each other in cells6,11.
When ERK5 is activated by MEK5 this leads to autopho-
sphorylation of the ERK5 C-terminus, which promotes tran-
scriptional activity11. It is known that inhibitor binding can alter
the dynamic ensemble of kinase conformations to stabilise a
speciﬁc conformation52. The crystal structure of ERK5 in com-
plex with compound 25 shows that ERK5 is in an ‘active’ con-
formation using PKA in complex with ATP and PKI as a
reference (Supplementary Fig. 7). Interestingly, comparison of the
crystal structures of ERK5 in complex with compound 25 (PDB
4B99) and with ATP and the PB1 domain of MEK5 (PDB 4IC7)
(Supplementary Fig. 7) reveals differences in the conformation of
the activation-loop and the orientation of the αC-helix that might
propagate to changes in the C-terminal portion of the protein
(however, both of these regions are also involved in crystal lattice
contacts so caution should be exercised in the interpretation of
the observed differences). To assess the potential impact of
AX15836 binding to ERK5 we conducted molecular dynamic
simulations. The binding energy was less favourable for AX15836
compared to compound 26, however, there was a reduction in the
ﬂexibility of the activation-loop most notably at positions 215 and
216—adjacent to the TEY motif at 218–220 (Supplementary
Fig. 8). These observations suggest that either the conformational
Fig. 4 Binding of compound 26 and AX15836 to the ERK5 kinase domain is required for paradoxical ERK5:MEF2D transcriptional activation. a–d and
h–k HEK293 cells were transfected with GAL4-MEF2D, GAL4:LUC and CMV:Renilla together with wild-type HA-ERK5 (full length) and either HA-L189F
ERK5 (a, h), HA-G199C ERK5 (b, i), HA-I115V ERK5 (c, j) or HA-D143G ERK5 (d, k) and EGFP then 4 h post transfection treated with compound 26 (a–d)
or AX15836 (h–k) at the concentrations indicated. Twenty-four hours post transfection, cells were lysed and ﬁreﬂy luciferase activity was measured and
normalised to Renilla. The results are presented as the mean of three experiments ± SEM. Source data are provided as a Source Data ﬁle. e–g HEK293 cells
were transfected with GAL4-MEF2D, GAL4:LUC and CMV:Renilla together with wild-type HA-ERK5 (full length) and either HA-L189F ERK5 (e), HA-
G199C ERK5 (f) or HA-I115V ERK5 (g) and EGFP-MEK5D then 4 h post transfection treated with compound 26 at the concentrations indicated. Twenty-
four hours post transfection, cells were lysed and processed as in (a–d and h–k).
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changes in the kinase domain are involved in interactions
between the kinase domain and C-terminus, or that the inhibitor
directly blocks such interactions. Further molecular analysis is
required to characterise these intramolecular interactions to fully
validate this model.
Paradoxical activation of ERK5 is the second major hurdle that
ERK5 inhibitor programmes have encountered. The ﬁrst hurdle
emerged from studies with the founding ERK5 inhibitor, XMD8-
92. This compound is tenfold more selective for ERK5 over other
kinases tested and phenocopied siRNA knockdown of
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ERK518,27,33,53–56. Subsequently, Lin et al.28 developed AX15836,
a next generation ERK5i with high selectivity and increased
potency for ERK5. However, XMD8-92 and AX15836 were found
to diverge in key cellular activities, leading to the suggestion that
XMD8-92 had ERK5-independent off-target effects. Indeed,
XMD8-92 was found to bind to BRD428. However, Lin et al.28
also noted a discrepancy between the effects of knockdown
of ERK5 and ERK5 inhibition by AX15836; knockdown of ERK5
Fig. 5 Compound 26 and AX15836 promote ERK5 nuclear localisation. a HEK293 cells were transfected with GST-ERK5 C-term, HA-ERK5 ΔTAD, GST,
HA, EGFP-MEK5D or GFP as indicated. Four hours post transfection, cells were treated with compound 26, AX15836 (AX), SCH772984 (SCH) or
DMSO as control (0) at the concentrations indicated for 24 h then the cells were lysed. Lysates were incubated with glutathione sepharose to precipitate
GST-ERK5 C-term and measure co-pulldown of HA-ERK5 ΔTAD. Pulldowns (PD) were immuno-blotted (IB) for GST-ERK5 C-term using ERK5 (C-terminal)
antibodies and HA-ERK5 ΔTAD using HA antibodies. To measure expression, whole-cell extracts (WCE) were blotted using ERK5 (C-terminal), HA and
MEK5. Phosphorylation of ERK5 by MEK5D was measured using phospho-ERK5 TEY antibodies. Source data are provided as a Source Data ﬁle. b HEK293
cells were transfected with either myc-tag or myc-BRAFV600E as indicated. Four hours post transfection, cells were treated with 0.1 µM SCH772984 (SCH)
or DMSO as control (0). Cells were harvested and immuno-blotted for myc (for expression of myc-BRAFV600E), phospho-T359 RSK and total RSK. A
representative image of three independent experiments is shown. Source data are provided as a Source Data ﬁle. c HeLa cells were transfected with wild-
type HA-ERK5 and either EGFP or EGFP-MEK5D. Twenty-four hours post transfection, cells were treated with compound 26, AX15836 or DMSO as
indicated. Thirty minutes after treatment cells were ﬁxed, permeabilised, blocked and stained with anti-HA then donkey-anti-mouse 568 Alexaﬂuor and
DAPI. Images were captured by high-content ﬂuorescence microscopy. d and e HeLa cells were transfected with wild-type HA-ERK5 and either EGFP or
EGFP-MEK5D. Four hours post transfection, cells were treated with compound 26 (d), AX15836 (e) or DMSO as indicated. Twenty-four hours post
transfection, cells were ﬁxed, permeabilised, blocked and stained with anti-HA then donkey-anti-mouse 568 Alexaﬂuor and DAPI. High-content microscopy
was used to determine the levels of nuclear and cytosolic HA-ERK5 staining. Results are presented as the % of transfected cells with nuclear≥cytosolic HA
staining of three independent experiments ± SEM. Source data are provided as a Source Data ﬁle. f HeLa cells were transfected as in (d) and (e) then treated
with compound 26 or AX15836 for the times indicated. Cells were then treated and processed as in (d and e). g HeLa cells were treated with 0.1 µM
compound 26, AX15836 or DMSO for 30min. Cells were harvested and the cytosolic and nuclear fractions were isolated and immuno-blotted for ERK5,
MEK1 (cytosolic marker) and lamin A/C (nuclear marker). A representative image of three independent experiments is shown. Source data are provided as a
Source Data ﬁle. h HeLa cells were transfected with wild-type HA-ERK5, HA-I115V ERK5, HA-D143G ERK5, HA-L189F ERK5 or HA-G199C ERK5 and EGFP.
Twenty-four hours post transfection, cells were treated and processed as in (d). i HeLa cells were transfected with wild-type HA-ERK5, HA-I115V ERK5, HA-
D143G ERK5, HA-L189F ERK5 or HA-G199C ERK5 and EGFP. Four hours post transfection, cells were treated with compound 26 or DMSO as indicated.
Twenty-four post transfection, cells were treated and processed as in (d).
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Fig. 6 ERK5i induce expression from the KLF2 promoter and is dependent on ERK5 TAD. a HEK293 cells were transfected with KLF2:LUC and CMV:
Renilla together with either FLAG or FLAG-MEF2D and either HA or HA-ERK5 (full length), and either EGFP (control) or EGFP-MEK5D as indicated.
Twenty-four hours post transfection, cells were lysed and ﬁreﬂy luciferase activity was measured and normalised to Renilla. The results are presented as
the mean of three independent experiments ± SEM. Source data are provided as a Source Data ﬁle. b HEK293 cells were transfected with KLF2:LUC and
CMV:Renilla together with FLAG and HA, with either EGFP or EGFP-MEK5D (to activate endogenous ERK5). Four hours post transfection, cells transfected
with KLF2:LUC and CMV:Renilla together with FLAG, HA and EGFP were treated with either compound 26, AX15836 or DMSO (control) at the
concentrations indicated. Cells transfected with KLF2:LUC and CMV:Renilla together with FLAG, HA and EGFP-MEK5D were treated with DMSO. Twenty-
four hours post transfection, cells were lysed and ﬁreﬂy luciferase activity was measured and normalised to Renilla. The results are presented as % KLF2
promoter activity where MEK5D-driven (through endogenous ERK5) KLF2 promoter activity is 100% (mean of three independent experiments ± SEM).
Source data are provided as a Source Data ﬁle. c HEK293 cells were transfected with KLF2:LUC and CMV:Renilla, together with FLAG-MEF2D and either
HA-ERK5 (full length) or HA-ERK5 ΔTAD, and either EGFP (control) or EGFP-MEK5D. Four hours post transfection cells were treated with either 300 nM
AX15836 or DMSO (control). Twenty-four hours post transfection cells were lysed and processed as in b.
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prevented IL-6 and IL-8 production from HUVEC and BEAS-2B
cells, but AX15836 did not. Our results now provide a possible
explanation for why AX15836 was unable to phenocopy ERK5
knockdown; namely because AX15836 paradoxically activates
ERK5 transcriptional activity. Further studies are now required to
address the role of transcriptional regulation by ERK5 in this and
other models.
These observations raise two critical questions moving forward.
First, since ERK5 kinase inhibitors can activate the ERK5 TAD,
which of these two activities (kinase domain or TAD) is critical
for the biological effects of ERK5 in diseases such as cancer and
inﬂammation? In this context it is notable that naturally occur-
ring ERK5 splice variants exist that lack either the C-terminal
TAD or the N-terminus, including the kinase N-lobe (such that
the kinase will be inactive)42,57; it will be interesting to see if the
embryonic lethality associated with ERK5 knockout is replicated
by a ∆TAD deletion or a catalytically inactive kinase mutant. The
second critical question is whether paradoxical activation by
ERK5i can be engineered out? The answer to this question is
likely to be yes. The relative magnitude of effect of compound 26
and AX15836 (Fig. 2) suggests there is scope for this effect to be
eliminated through the combination of structure-guided drug
design and cell-based screening. Using BRAF as an example,
success has been seen with the paradox-breaking compounds,
PLX7904 and PLX8394. These inhibitors suppress the growth of
melanoma cells with BRAFV600E but, unlike vemurafenib, do not
activate ERK1/2 signalling in cells harbouring mutant KRAS or in
cells that have activated tyrosine kinases58.
To date, two mechanisms of paradoxical pathway activation have
been described for kinase inhibitors. The ﬁrst is by priming kinases
for activation. For example, selective inhibitors of PKB promote its
membrane localisation, phosphorylation of its regulatory sites
(T308 and S473) by the upstream kinases, PDK1 and mTOR,
respectively52, and acquisition of a phosphatase-resistant con-
formation59. As a result, when the inhibitor dissociates, PKB is
catalytically active and primed for activity50. Similar observations
have been made for PKC60, PKD61 and AMPK62. The second way
small-molecule kinase inhibitors can paradoxically activate a path-
way is by transactivation of non-drug-bound isoforms in homo- or
hetero-dimer pairs. The most notable example are the RAF inhi-
bitors such as vemurafenib. This inhibitor was developed to target
the BRAFV600E mutant and shows potent anti-tumour effects in
tumours carrying this mutation. Critically, while vemurafenib can
inhibit BRAFV600E, which signals as a monomer, it can activate
wild-type RAF kinases that act as RAS-dependent CRAF-CRAF
homodimers or BRAF-CRAF heterodimers. In this case, the drug-
bound protomer trans-activates the drug-free protomer, leading to
pathway activation. Inhibitor binding also promoted membrane
localisation of RAF and interaction with RAS-GTP63,64. Similar
observations have been made for bosutinib binding to the pseu-
dokinase HER365,66 to induce an EGFR-dependent proliferative
signal67. What we observe with inhibitor binding to ERK5 presents
a third and entirely new way that kinase inhibitors can cause
paradoxical activation of their intended target. Direct binding of the
inhibitor to the kinase causes intramolecular changes that cause
activation of the target molecule. This is neither dependent on
priming phosphorylation and inhibitor dissociation, nor transacti-
vation of a dimer partner to induce phosphorylation of downstream
targets. We term this ‘direct paradoxical activation by kinase
inhibitors’.
In conclusion, we show that ERK5i paradoxically activate
ERK5 transcriptional activity by binding to the ERK5 catalytic
site and de-repressing the C-terminal TAD function; this repre-
sents a third model whereby kinase inhibitors paradoxically
activate their intended target. This may explain why the most up-
to-date ERK5i that lack BRD4 activity do not phenocopy ERK5
small-interfering RNA (siRNA) knockdown. As a result, caution
should be exercised when interpreting cellular data using com-
pound 26 (ERK5-IN-1/XMD17-109) or AX15836. Furthermore,
paradox-breaking ERK5i should be identiﬁed to progress our
understanding of ERK5 structure-function, ERK5 biology and to
inform ERK5 drug discovery programmes.
Materials and methods
Materials. Cell culture reagents were purchased from Invitrogen and Sigma.
Compounds 25 and 26 (ERK5-IN-1) were originally provided by Professor
Nathanael Gray and Dr. Jinhua Wang, Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical School, Boston, USA then latterly
compound 26 was purchased from Selleckchem. AX15836 and JQ1 are from
Tocris. BIX02189 is from Selleckchem. Anti-HA antibody for immunoblots was
provided by the Babraham Institute Monoclonal Facility40,41 and anti-HA (12CA5)
antibody for immuno-ﬂuorescence68 was from Roche/Sigma. Phospho-ERK5 TEY
(3371) antibody was from Cell Signaling Technology40,41. Phospho-T733 and
phospho-S754 ERK5 antibodies were a kind gift from Dr. Atanasio Pandiella,
University of Salamanca, Spain16. Anti-Flag antibody (M2) is from Sigma69. Anti-
MEK5 antibody (AB3184) is from EMD Millipore22, anti-lamin A/C (636)70, ERK5
(C-7)26 and myc (9E10)71 antibodies are from Santa Cruz and anti-MEK1/272,
phospho-T359 RSK73 and total RSK74 from Cell Signaling Technology. Secondary
antibodies were from BioRad40,41.
Methods
Cell culture. HEK293 and HeLa were cultured in Dulbecco's modiﬁed Eagle
medium (DMEM) supplemented with 10% FBS at 37 °C in an atmosphere of 5%
CO2 and 95% humidity.
Plasmids. The HA-ERK5 and EGFP-MEK5D constructs have been described
previously and were derived from constructs provided by J.D. Lee. GAL4-MEF2D
(GAL4 DNA binding domain fused to a.a. 87–428 of rat MEF2D) was from J.C.
McDermott, Centre for Research in Biomolecular Interactions, York University,
Toronto, Canada; GAL4:LUC reporter from D. Gillespie, University of Glasgow,
Glasgow, UK; GST-ERK5 C-term (aa 401–815) was from J. Lizcano, Universitat
Autònoma de Barcelona, Spain. A luciferase reporter gene driven by the KLF2
promoter (−924 + 14) was a kind gift from J. Abe, Department of Cardiology,
Division of Internal Medicine, The University of Texas MD Anderson Cancer
Centre, Houston, Texas, U.S.A. p3XFlag-MEF2D was a gift from R. Prywes
(Addgene plasmid # 32964).
HA-ERK5 D182A, I115V, D143G, L189F, G199C, S754A, S754D, ΔTAD,
Y741*, L664*, A579*, K506* and P435* were made by site-directed mutagenesis
using either QuikChange Site-Directed Mutagenesis kit (Agilent) or Q5 Site-
Directed Mutagenesis Kit (New England Biolabs) and veriﬁed by ABI automated
sequencing.
Luciferase assays. In 96-well tissue culture plates with opaque sides (Thistle
Scientiﬁc), HEK293 were transfected with pEGFP-MEK5D, pCANHA-ERK5,
GAL4-MEF2D, 5XGAL4-Luciferase and CMV-renilla using Lipofectamine 2000
according to the manufacturer’s instructions. Compounds 25 and 26, AX15836 and
BIX02189 were added at concentrations indicated, 4 h post transfection. After a
further 20 h, cells were harvested and processed for ﬁreﬂy and renilla luciferase
activity using the Promega Dual Luciferase Reporter assay according to the man-
ufacturer’s instructions.
For KLF2-promoter experiments, HEK293 were transfected with pEGFP-
MEK5D, pCANHA-ERK5, p3XFlag-MEF2D, luciferase reporter gene driven by the
KLF2 promoter (−924 to + 14) and CMV-Renilla using Lipofectamine 2000
according to the manufacturer’s instructions and treated as above.
Antibody conditions. Antibodies and conditions used are given in Table 1.
Immunoblot analysis. For western blotting, 6 cm dishes (Thermo Scientiﬁc) were
routinely transfected as described then treated with compound 26, AX15836,
SCH772984 or DMSO at the indicated concentrations and for the indicated times
prior to harvesting and lysed to prepare whole-cell extracts in 150 µl TG lysis buffer
(20 mM Tris-HCl pH 7.5, 137 mM NaCl, 1 mM, EGTA, 1% v/v Triton X-100, 10%
v/v glycerol, 1.5 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, 10 µg/ml leupeptin, 10
μg/ml aprotinin, 50 mM NaF). Samples were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels, then trans-
ferred to PVDF membranes. Membranes were blocked in 5% milk-TBST and
incubated with antibody overnight, shaking at 4 °C. The following day, membranes
were washed 3 times with TBS-T, incubated for 30 min–1 h with HRP-secondary
antibody and the bands imaged with ECL and ﬁlm. Films were scanned using an
EPSON scanner, and images rotated in Adobe Photoshop Elements and the image
cut and pasted into Adobe Illustrator to prepare the ﬁgures. Alternatively, blots
were incubated with IRDye 680 or 800 anti-mouse or anti-rabbit secondary
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antibodies and visualised using an Odyssey CLx Li-COR scanner. All uncropped
blots and scans are in the Source Data ﬁle.
GST pull-downs. For GST pull-downs, 10 cm dishes (Thermo Scientiﬁc) were
routinely transfected as described then used to prepare whole-cell extracts in 500 µl
TG lysis buffer. Two-hundred microlitres lysate was incubated with 20 µl glu-
tathione sepharose 4B (GE Healthcare) (50% slurry in PBS) at 4 °C end-over-end
for 2 h. Glutathione-sepharose conjugates were washed two times with TG lysis
buffer, spinning at 3000 rcf for 1 min, then subjected to SDS-PAGE and immune
blotting using the antibodies indicated.
Nuclear-cytosolic fractionation. HeLa cells were seeded in 10 cm dishes (Thermo
Scientiﬁc) and allowed to settle for 24 h. Cells were then treated with 0.1 µM com-
pound 26, AX15836 or DMSO control for 30min. Cells were harvested by trypsi-
nisation and centrifugation and snap frozen. The cell pellets were thawed on ice re-
suspended in ice cold buffer A (10mM Hepes pH 7.9, 1.5mM MgCl2, 10mM KCl,
0.1mM EDTA, 1mM Na3VO4, 1 mM PMSF, 10 µg/ml leupeptin, 10 μg/ml aprotinin,
50mM NaF). Cell suspensions were incubated on ice to allow cells to swell. In all,
0.1% NP-40 was added and mixed by gently pipetting up and down. The cell sus-
pension was then passed through a 25 G needle to disrupt the cell membrane. The
homogenate was centrifuged at 800 rcf to pellet the nuclei. The cytosolic fraction was
transferred to a fresh tube and centrifuged three times at 10,000 rcf and supernatant
removed to pellet any remaining nuclei. NaCl was added to a ﬁnal concentration of
137mM and glycerol to 100%. The nuclear fraction was re-suspended in buffer A and
centrifuged at 800 rcf and washed three times with buffer A to remove any residual
cytosol. The nuclei pellet was re-suspended in RIPA buffer (50mM Tris-HCl pH 8,
150mM NaCl, 1% v/v Triton X-100, 1% w/v sodium deoxycholate, 0.1% w/v SDS, 1
mM Na3VO4, 1 mM PMSF, 10 µg/ml leupeptin, 10 μg/ml aprotinin, 50 mM NaF)
supplemented with 2.25U benzonase/ml and incubated at 4 °C for 1 h end-over-end
and occasionally vortexing. Samples were subjected to SDS-PAGE and immuno-
blotted with the antibodies indicated.
Mass spectrometry. MEF2D bands were cut from Coomassie-stained gels,
reduced, carbamidomethylated and digested overnight at 30 °C in 25 mM ammo-
nium bicarbonate containing 10 ng/ml of protease (modiﬁed trypsin (Promega) or
elastase (Promega)). Phosphopeptides were enriched using titanium dioxide beads
(Titansphere, GL Sciences) and glycolic acid as competitor. Enriched phospho-
peptides, or unfractionated digests, were analysed by nano liquid
chromatography–mass spectrometry (LC-MS/MS) on a QExactive Plus mass
spectrometer (Thermo Scientiﬁc) ﬁtted with a nanoelectrospray ion-source
(Proxeon). Peptides were separated on a reversed-phase column (0.075 × 150 mm;
ReproSil-Pur 120 C18-AQ 3mm) using an acetonitrile gradient (5–40% in 30 min
at 300 nl/min) containing 0.1% formic acid. Full scan data were acquired over the
m/z range 350–1800 at a nominal resolution setting of 70,000, followed by up to 10
higher-energy collisional dissociation (HCD) spectra at 27% relative collision
energy. Analyses of the digests with targeted MS/MS of the identiﬁed phospho-
peptides were done similarly, but with HCD fragmentation at 35% relative collision
energy. Mass spectral data were searched against the human entries of the Uniprot
15.14 database using Mascot software (Matrix Science) and all putative phospho-
peptide MS/MS spectra were manually validated. Apparent stoichiometries of
phosphorylation were calculated from the peak areas of the extracted ion
chromatograms of the phospho- and corresponding nonphosphopeptides in LC-
MS runs of unfractionated digests as in ref. 40.
(Phospho)peptides were identiﬁed from mass spectrometry data using Peaks
Studio V7 (Bioinformatics Solutions Inc) and manually validated, while
quantitative analyses were done with the aid of Skyline Software (MacCoss Lab,
Washington University).
Molecular dynamics simulations. The structure of ERK537 co-crystallised with
the speciﬁc inhibitor compound 25 (PDB: 4B99) was used as a starting model for
molecular dynamics simulation. All solvent molecules were removed, and com-
pound 25 was extracted from the model. Missing loops were built with MOD-
ELLER (v9.19)75,76 via UCSF Chimera77. Mutants were modelled in UCSF
Chimera. Compound 25 was modiﬁed in Avogadro (v.1.9)78 to create compound
26 using the published structure as a ref. 37, changing the R1 group from a
methoxy to ethoxy moiety and adding hydrogen atoms. The ligand was then
parameterised using Gasteiger point charges in the AMBER ff99sb79 force ﬁeld for
simulation using Antechamber80, and prepared for GROMACS using ACPYPE81.
The complexes were then prepared in GROMACS82, parameterised in ff99sb and
neutralised with sodium and chloride ions to a ﬁnal concentration of 0.1 M, prior
to being subject to minimisation and equilibration. Brieﬂy, a steepest descent
gradient of maximum 5000 steps was used to minimise the complexes, which
converged on an Fmax < 1000 kJ/mol/nm in <2000 steps. The complexes were then
subject to 200 ps equilibration in the NvT ensemble using a 2 fs timestep and Nose-
Hoover temperature coupling at 300 K; all atoms were subject to position restraints.
Subsequent equilibration in the NpT ensemble was also conducted under position
restraints at a 2 fs timestep, with Parinello-Rahman barostat at 1 bar. Finally,
position restraints were released and three parallel production MD simulations
were conducted for a 10 ns.
The g_mmpbs83 package was used to calculate binding energies between ligand
and protein. The ﬁnal 2 ns of converged simulation time was used for each of the
simulations, totalling 201 snapshots from 8–10 ns. The binding energies were
converted from kJ/mol to the more commonly used kcal/mol and averaged.
To model AX15836 binding to ERK5, the method outlined above for compound
26 was used and run for 100 ns and the root mean squared ﬂuctuation (RMSF) of
each residue was calculated for the period 10–100 ns.
High-content microscopy: equipment and settings. HeLa cells were seeded in
Cell CarrierTM-96 plates (Perkin Elmer) then transfected with pCANHA-ERK5
and pEGFP-MEK5D using Extreme-Gene 9 (Sigma) as indicated. Cells were
treated with compound 26 or DMSO at the concentrations and for the indicated
times prior to ﬁxing with 4% paraformaldehyde for 30 min at 25 °C. The cells were
then blocked with Blocking Buffer (1x PBS/5% goat serum/0.3% Triton™ X-100).
Slides were then incubated with anti-HA (12CA5) 1:100 in Antibody Dilution
Buffer: (1X PBS/1% BSA/0.3% Triton™ X-100) overnight at 4 °C. Slides were
washed 3 times with PBS for 5 min per wash then incubated with 1:1000 donkey-
anti-mouse 568 Alexa Fluor (Invitrogen) and 1 µg/ml DAPI. Slides were then
washed three times for 5 min per wash and left in PBS for imaging.
Cells were imaged using In Cell 6000 at room temperature, with 20x objective lens
acquiring GFP, DAPI and dsRed using the InCell software settings. Single section
images of xy planes with pixel dimensions 325 x 325 nm and 16 bit image (2048 ×
2048 pixels). The ﬂuorochromes used were 568 Alexa Fluor (Laser: 568 nm, Filter:
Table 1 Antibodies and conditions used.
Antibody Supplier Catalogue number Dilution/ diluent Technique
Anti-MEK5 EMD Millipore AB3184 1:500/5% milk TBS-T Immuno-blotting
Anti-phospho-
TEY ERK5
Cell Signaling 3371 1:500 / 5% BSA TBS-T Immuno-blotting
Anti-FLAG M2 Roche/Sigma F3165 1:2000 / 5% milk TBS-T Immuno-blotting
Anti-HA (12CA5) Sigma 11583816001 5 µg/ml in Antibody Dilution Buffer: (1x
PBS/1% BSA/0.3% Triton™ X-100)
Immuno-
ﬂuorescence
Anti-HA Babraham Institute Monoclonal Facility N/A 1:10/5% milk TBS-T Immuno-blotting
Anti-phospho-T733 Gift from Dr. Atanasio Pandiella,
University of Salamanca, Spain.
N/A 1:250/5% milk TBS-T Immuno-blotting
Anti-phospho-S754 Gift from Dr. Atanasio Pandiella,
University of Salamanca, Spain.
N/A 1:250/5% milk TBS-T Immuno-blotting
Anti-myc (9E10) Santa Cruz SC-40 1:1000/5% milk TBS-T Immuno-blotting
Anti-phospho-
T359 RSK
Cell Signaling 8753 1:1000/5% milk TBS-T Immuno-blotting
Anti-RSK Cell Signaling 9355 1:1000/5% milk TBS-T Immuno-blotting
Anti-MEK1/2 Cell Signaling 9122 1:1000/5% milk TBS-T Immuno-blotting
Anti-Lamin A/C Santa Cruz SC-7292 1:500/5% milk TBS-T Immuno-blotting
Anti-ERK5 (C-7) Santa Cruz SC-398015 1:1000/5% milk TBS-T Immuno-blotting
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Texas Red, Excitation max: 578 nm, and Emission max: 603 nm), DAPI (Laser: 405
nm, Filter: DAPI, Excitation max: 350 nm, and Emission max: 470 nm), and GFP
(Laser:488 nm, Filter: FITC, Excitation max: 488 nm, and Emission max: 510 nm).
Results were analysed using In Cell Analyser Workstation 3.7.2 to determine the level
of nuclear and cytosolic ERK5. In the Assay Parameters for Nuclei and Cells,
Segmentation of nuclei was set to Top-Hat with a minimum area of 50 µm2 and
Segmentation of cells to Collar with a radius of 2 µm. The Assay Measures were
Nuclei Area, Nuc1/(FormFactor), Nuclei Intensity; Reference, Nuc/Cell Intensity, Nuc
Intensity, Cell Intensity; Cell tracking, Label, Linked Track ID; and Filters, threshold,
Nuc1/(Form Factor), Nuclei. The Cell-by-Cell data was exported to Microsoft Excel as
a.csv ﬁle. Transfected cells were identiﬁed by having a reading > than 2x background
intensity. The % of cells with higher nuclear ERK5 staining to cytosolic ERK5 staining
was calculated for each experimental well.
Representative.tiff images we merged in ImageJ and the scale bar added. The
images were converted to RGB colour, or the red channel displayed as greyscale
alone. The brightness/contrast minimum and maximum was ﬁxed to the same
values for each image.
Statistical analysis. Depending on the scientiﬁc question, in particular the
number of conditions compared, and the experimental design, independent or
paired t-tests or one-way or repeated measured analysis of variances (ANOVAs)
were run to establish statistical signiﬁcance (p < 0.05). ANOVAs were followed by
post-hoc tests with Holm–Sidak correction for multiple comparisons. When the
experiments were comparing curves, area under the curves were used for the
statistical analyses. Where appropriate, to show signiﬁcance or not, the p-values are
displayed on the graphs.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data sets analysed during the current study are available in the following repositories:
coordinates for the structures of the ERK5-Cpd 25, ERK5-ATP-MEK5 PB1 domain, and
PKA-ATP-PKI complexes were retrieved from the Protein Databank in Europe (PDBe)
at https://www.ebi.ac.uk/pdbe/ using the accession codes 4B99, 4IC7 and 4WB5,
respectively; protein sequences for human AURKA, AURKB, DCLK1, DLCK2, DCLK3,
ERK1, ERK2, ERK3, ERK4, ERK5, ERK6, ERK7, ERK8, LRRK2, PLK1, PLK2, PLK3,
PLK4, RIPK1, RIPK2 and RIPK5, and for human, mouse and rat MEF2D were retrieved
from the UniProt knowledge Base at https://www.uniprot.org/ using the accession codes
O14965, Q96GD4, O15075, Q8N568, Q9C098, P27361, P28482, Q16659, P31152,
Q13164, P53778, Q8TD08, Q5S007, P53350, Q9NYY3, Q9H4B4, O00444, Q13546,
O43353, Q6XUX3, Q14814, Q63943 and O89038, respectively. The source data
underlying Figs. 2a–h, 3d–k, 4a–k, 5a, b, d–i and 6a–c, and Supplementary Figs. S1B–D,
S2A–F, S3C, S4C, D, S5, S6, S8A–C are provided as a Source Data ﬁle. All the other data
supporting the ﬁndings of this study are available within the article and its
supplementary information ﬁles and from the corresponding author on reasonable
request.
Code availability
All code used to generate and analyse the Molecular Dynamic Simulations can be
accessed here https://osf.io/thfx3/
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